News

• Five Chinese companies join UN’s MPP for Covid-19 medicines
• South Korean companies to make generic Bridion and COVID-19 drugs
• Revlimid (lenalidomide) generics launch across Europe
• Cancer and diabetes generic treatments receive positive opinion from EMA’s CHMP

Research

• Relevance of NTI to the treatment of epilepsy
• What is the meaning of a narrow therapeutic index?
• Consequences of generics being favoured by healthcare providers
• What is meant by a generic medication and generic equivalence?

General

• Pharmaceutical companies in Latin America and the Caribbean
• Canada calls for support to national pharmacare and generics industry
• UK NHS faces drug shortages
• High drug bills? Turn to your pharmacist for help

News

• EMA recommends approval of bevacizumab biosimilar Vegzelma
• FDA approves pegfilgrastim and rituximab biosimilars
• Byooviz: first ophthalmology biosimilar launches in US
• Biocon: cancer biosimilar launch in Canada and US$90 million Malaysia deal

Research

• Adalimumab biosimilar MSB11022: PK and tolerability of autoinjector versus pre-filled syringe
• No trends in biosimilars uptake levels in the US, reveals study
• The impact of biosimilar insulins on public spending in Brazil
• Challenges with implementing benefit-sharing programmes for biologicals in Europe

General

• American Academy of Ophthalmology biosimilars guidance details
• Biosimilars approved in the US
• Biosimilars approved in Europe
• Current status of monoclonal antibody biosimilars approved in Latin America

• Latin American Forum
• Non‐Biological Complex Drugs
• Country Focus

• Guidelines
• Policies & Legislation
• Reports

• Conferences
• Sponsored Articles
• Sponsored Links